Thomas Charles Heineman net worth and biography

Thomas Heineman Biography and Net Worth

Chief Medical Officer of Oncolytics Biotech

Prior to joining Oncolytics, Dr. Thomas Heineman was Senior Vice President and Head of Clinical Development at Denovo Biopharma. Prior to his time at Denovo, he served as Vice President and Head of Clinical Development at both Genocea Biosciences and Halozyme Therapeutics. At Halozyme, Dr. Heineman was also Head of Translational Medicine and oversaw clinical trials in indications such as breast and pancreatic cancer. Dr. Heineman’s experience further extends to big pharma and academia, as he previously worked as Senior Director, Global Clinical Research and Development at GlaxoSmithKline and as an Associate Professor at the Saint Louis University School of Medicine. Dr. Heineman has co-authored over 60 peer-reviewed publications and is board certified in Internal Medicine and Infectious Diseases. He completed his fellowship in Infectious Diseases at the National Institutes of Health and his internship and residency at the University of Maryland. Dr. Heineman earned his MD and PhD in Virology at the University of Chicago.

What is Thomas Charles Heineman's net worth?: The estimated net worth of Thomas Charles Heineman is at least $237.06 thousand as of February 12th, 2026. Dr. Heineman owns 282,818 shares of Oncolytics Biotech stock worth more than $237,058 as of September 1st. This net worth approximation does not reflect any other assets that Dr. Heineman may own. Learn More about Thomas Charles Heineman's net worth.
How do I contact Thomas Charles Heineman?: The corporate mailing address for Dr. Heineman and other Oncolytics Biotech executives is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. Oncolytics Biotech can also be reached via phone at (403) 670-7377 and via email at [email protected]. Learn More on Thomas Charles Heineman's contact information.
Has Thomas Charles Heineman been buying or selling shares of Oncolytics Biotech?: Thomas Charles Heineman has not been actively trading shares of Oncolytics Biotech in the last ninety days. Most recently, on Thursday, February 12th, Thomas Charles Heineman bought 12,132 shares of Oncolytics Biotech stock. The stock was acquired at an average cost of $0.83 per share, with a total value of $10,069.56. Following the completion of the transaction, the insider now directly owns 282,818 shares of the company's stock, valued at $234,738.94. Learn More on Thomas Charles Heineman's trading history.
Who are Oncolytics Biotech's active insiders?: Oncolytics Biotech's insider roster includes Patricia Andrews (Director), Andrew Aromando (Chief Business Officer), Deborah Brown (Director), Allison Hagerman (Chief Technology Officer), Thomas Heineman (Chief Medical Officer), Jared Kelly (Chief Executive Officer & Director), Kirk Look (CFO), James Parsons (Director), and Bernd Seizinger (Director). Learn More on Oncolytics Biotech's active insiders.
Are insiders buying or selling shares of Oncolytics Biotech?: During the last year, Oncolytics Biotech insiders bought shares 14 times. They purchased a total of 404,282 shares worth more than $363,231.56. The most recent insider tranaction occured on March, 12th when CEO Jared Kelly bought 5,050 shares worth more than $4,848.00. Insiders at Oncolytics Biotech own 0.1% of the company. Learn More about insider trades at Oncolytics Biotech.
Information on this page was last updated on 3/12/2026.

Thomas Charles Heineman Insider Trading History at Oncolytics Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/12/2026	Buy	12,132	$0.83	$10,069.56	282,818

Thomas Charles Heineman Buying and Selling Activity at Oncolytics Biotech

Oncolytics Biotech Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Today's Range

Now: $0.84

$0.83

$0.87

50 Day Range

MA: $0.85

$0.75

$0.96

2 Week Range

Now: $0.84

$0.73

$1.51

Volume

428,783 shs

Average Volume

644,143 shs

Market Capitalization

$106.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13